CoChat

Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model

Open access

The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.

Abstract

Patients with inflammatory bowel disease (IBD) have an increased risk of colon cancer. However, the immune cells and cytokines that mediate the transition from intestinal inflammation to cancer are poorly understood. We show that bacteria-induced colon cancer is accompanied by differential accumulation of IL-17(+)IL-22(+) colonic innate lymphoid cells (cILCs), which are phenotypically distinct from LTi and NK-22 cells, and that their depletion in mice with dysplastic inflammation blocks the development of invasive colon cancer. Analysis of the functional role of distinct Type 17 cytokines shows that although blockade of IL-17 inhibits some parameters of intestinal inflammation, reduction in dysplasia and colorectal cancer (CRC) requires neutralization of IL-22 indicating a unique role for IL-22 in the maintenance of cancer in this model. Mechanistic analyses showed that IL-22 selectively acts on epithelial cells to induce Stat3 phosphorylation and proliferation. Importantly, we could detect IL-22(+)CD3(+) and IL-22(+)CD3(−) cells in human CRC. Our results describe a new activity of IL-22 in the colon as a nonredundant mediator of the inflammatory cascade required for perpetuation of CRC, highlighting the IL-22 axis as a novel therapeutic target in colon cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20122308

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. IL-23 signature genes are increased in aberrant crypt lesions of Hh+AOM-treated mice. (A) Treatment scheme (left) and H&E-stained invasive colorectal-carcinoma in Hh+AOM-treated 129SvEv.Rag−/− mice (right; bar, 100 µm). Arrows represent atypical glands breaching the muscularis mucosa. (B) Quantitative PCR analysis showing levels of mRNA of the cytokines Il-23, Il-17, and Il-22, the matrix metalloproteinases Mmp9 and Mmp2, the EGF receptor ligand amphiregulin (Areg), and Hif1a, Vegfa, and Ptgs2 (Cox-2) in tumors versus surrounding normal tissue (n = 5–7). Graphs show a representative experiment out of two independently performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001, paired Student’s t test.
Figure 1. IL-23 signature genes are increased in aberrant crypt lesions of Hh+AOM-treated mice. (A) Treatment scheme (left) and H&E-stained invasive colorectal-carcinoma in Hh+AOM-treated 129SvEv.Rag−/− mice (right; bar, 100 µm). Arrows represent atypical glands breaching the muscularis mucosa. (B) Quantitative PCR analysis showing levels of mRNA of the cytokines Il-23, Il-17, and Il-22, the matrix metalloproteinases Mmp9 and Mmp2, the EGF receptor ligand amphiregulin (Areg), and Hif1a, Vegfa, and Ptgs2 (Cox-2) in tumors versus surrounding normal tissue (n = 5–7). Graphs show a representative experiment out of two independently performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001, paired Student’s t test.CC BY-NC-SA · PubMed Central
Figure 2. Nkp46−CD4− cILCs accumulate during H. hepaticus–driven cancer. (A–C) Flow cytometry on cLP cells of uninfected and Hh+AOM mice. Composition (B), frequency, and numbers of cILC (n = 5; C). (D) Surface marker expression on cILC from uninfected or Hh+AOM mice. (E) Representative immunofluorescence of an Hh+AOM CRC. Arrows indicate invasive crypts. Data are shown as means and SEM. Results are representative of at least two independent experiments. *, P < 0.05; **, P < 0.01, Mann-Whitney nonparametric test.
Figure 2. Nkp46−CD4− cILCs accumulate during H. hepaticus–driven cancer. (A–C) Flow cytometry on cLP cells of uninfected and Hh+AOM mice. Composition (B), frequency, and numbers of cILC (n = 5; C). (D) Surface marker expression on cILC from uninfected or Hh+AOM mice. (E) Representative immunofluorescence of an Hh+AOM CRC. Arrows indicate invasive crypts. Data are shown as means and SEM. Results are representative of at least two independent experiments. *, P < 0.05; **, P < 0.01, Mann-Whitney nonparametric test.CC BY-NC-SA · PubMed Central
Figure 3. Colitis to cancer transition is dependent on ILC. (A) Treatment scheme. (B) Spleen mass (left), colitis (middle), and typhlitis (right) in isotype (n = 13) or anti-Thy1 (n = 11)–treated Hh+AOM mice. (C) Cytokines in supernatants of pooled cLP cells cultured overnight from one representative experiment of three independently performed experiments. (D) Flow cytometry of colonic CD11bhi Gr1hi granulocytes. (E) Aberrant crypt area on methylene blue–stained colons. (F) Representative photomicrographs (bars, 200 µm) of invasive CRC in an isotype treated mouse (left) and normal colon in an anti-Thy1–treated mouse (right). (G) Highest tumor grade per mouse. Data are shown as means. Results show a pool of two independent experiments (B, E, and G). **, P < 0.01; ***, P < 0.001, Mann-Whitney non parametric t test (B and E), Fisher’s square test (G).
Figure 3. Colitis to cancer transition is dependent on ILC. (A) Treatment scheme. (B) Spleen mass (left), colitis (middle), and typhlitis (right) in isotype (n = 13) or anti-Thy1 (n = 11)–treated Hh+AOM mice. (C) Cytokines in supernatants of pooled cLP cells cultured overnight from one representative experiment of three independently performed experiments. (D) Flow cytometry of colonic CD11bhi Gr1hi granulocytes. (E) Aberrant crypt area on methylene blue–stained colons. (F) Representative photomicrographs (bars, 200 µm) of invasive CRC in an isotype treated mouse (left) and normal colon in an anti-Thy1–treated mouse (right). (G) Highest tumor grade per mouse. Data are shown as means. Results show a pool of two independent experiments (B, E, and G). **, P < 0.01; ***, P < 0.001, Mann-Whitney non parametric t test (B and E), Fisher’s square test (G).CC BY-NC-SA · PubMed Central
Figure 4. Nkp46− CD4− lin− Thy1hi ILCs are the major source of IL-22 in Hh+AOM CRC. (A) Secretion of cytokines into the supernatant of overnight cultured cLP cells from uninfected or Hh+AOM-treated mice. (B) Intracellular cytokine stain gated on different ILC populations from uninfected or Hh+AOM-treated mice after 3 h culture of cLPs in the presence of monensin. (C–E) Characterization of IL-22 producers in cLPs of Hh+AOM-treated mice stimulated overnight in the presence of IL-23 and for 3 h with PMA, Ionomycin, and monensin (n = 5). (C) Intracellular stain with isotype (left) or anti–IL-22 (right). (D) Anti–IL-22 stains mostly Thy1hi (left) Nkp46− CD4− (right) cells. (E) IL-17 and IL-22 expression in Thy1hi cells. Data are shown as means and SEM. Results are representative of at least two independent experiments. *, P < 0.05, Mann-Whitney nonparametric test.
Figure 4. Nkp46− CD4− lin− Thy1hi ILCs are the major source of IL-22 in Hh+AOM CRC. (A) Secretion of cytokines into the supernatant of overnight cultured cLP cells from uninfected or Hh+AOM-treated mice. (B) Intracellular cytokine stain gated on different ILC populations from uninfected or Hh+AOM-treated mice after 3 h culture of cLPs in the presence of monensin. (C–E) Characterization of IL-22 producers in cLPs of Hh+AOM-treated mice stimulated overnight in the presence of IL-23 and for 3 h with PMA, Ionomycin, and monensin (n = 5). (C) Intracellular stain with isotype (left) or anti–IL-22 (right). (D) Anti–IL-22 stains mostly Thy1hi (left) Nkp46− CD4− (right) cells. (E) IL-17 and IL-22 expression in Thy1hi cells. Data are shown as means and SEM. Results are representative of at least two independent experiments. *, P < 0.05, Mann-Whitney nonparametric test.CC BY-NC-SA · PubMed Central
Figure 5. IL-22 drives cancer perpetuation. (A) Treatment scheme. (B) Spleen mass (left), colitis (middle), and typhlitis (right). Means (n = 9–14). Results are a pool of two independent experiments. (C) Representative photomicrographs of colons (bars, 200 µm). (D) Granulocyte frequencies (left) and numbers (right) in cLPs as analyzed by flow cytometry for Gr-1hi, CD11bhi, and F4-80−, Ly6Cint cells (n = 3–5). Data shown represent one out of two independent experiments. (E) CRC in antibody-treated Hh+AOM mice. Highest tumor grade per mouse. (F) Colonization with Hh. Results are a pool of two independent experiments (B, E, and F). Bars represent the mean value (B, D, and F). Significance refers to isotype control (B and E). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, one-way ANOVA with Bonferroni’s post test (B) or Fisher’s square test (E).
Figure 5. IL-22 drives cancer perpetuation. (A) Treatment scheme. (B) Spleen mass (left), colitis (middle), and typhlitis (right). Means (n = 9–14). Results are a pool of two independent experiments. (C) Representative photomicrographs of colons (bars, 200 µm). (D) Granulocyte frequencies (left) and numbers (right) in cLPs as analyzed by flow cytometry for Gr-1hi, CD11bhi, and F4-80−, Ly6Cint cells (n = 3–5). Data shown represent one out of two independent experiments. (E) CRC in antibody-treated Hh+AOM mice. Highest tumor grade per mouse. (F) Colonization with Hh. Results are a pool of two independent experiments (B, E, and F). Bars represent the mean value (B, D, and F). Significance refers to isotype control (B and E). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, one-way ANOVA with Bonferroni’s post test (B) or Fisher’s square test (E).CC BY-NC-SA · PubMed Central
Figure 6. IL-22R expression in colonic epithelial cells in the Hh+AOM model. (A) Expression of IL-22R is restricted to colonic epithelial cells. Quantitative PCR analysis of mRNA levels of Il-22r and Il-10r2, the two subunits of IL-22 receptor, in colonic epithelial cells (EC), stromal cells (SC), and cLPs. Mean and SEM of one representative experiment (n = 3) of two is shown. (B) Expression of IL-22R in dysplastic epithelial cells of 5-mo Hh+AOM-treated mice as assessed by immunohistochemistry. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001, one-way ANOVA with Bonferroni’s post test (A).
Figure 6. IL-22R expression in colonic epithelial cells in the Hh+AOM model. (A) Expression of IL-22R is restricted to colonic epithelial cells. Quantitative PCR analysis of mRNA levels of Il-22r and Il-10r2, the two subunits of IL-22 receptor, in colonic epithelial cells (EC), stromal cells (SC), and cLPs. Mean and SEM of one representative experiment (n = 3) of two is shown. (B) Expression of IL-22R in dysplastic epithelial cells of 5-mo Hh+AOM-treated mice as assessed by immunohistochemistry. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001, one-way ANOVA with Bonferroni’s post test (A).CC BY-NC-SA · PubMed Central
Figure 7. IL-22 regulates epithelial functions through Stat3 phosphorylation. (A–E) Hh+AOM-treated mice were injected with isotype control, anti–IL-22, anti-IL6R, anti–IL-17, or anti-Thy1 (B and E) for 1 wk. (A) Colonic phospho-Stat3-Y705 expression (bars, 25 µm). Arrows indicate pStat3+ cells in the cLP. (B) Immunoblot for phospho-Stat3 and total Stat3 in colonic epithelial and lamina propria cells. (C and D) Blocking of IL-22 reduces epithelial proliferation. (C) Ki-67 expression in freshly isolated EC from Hh+AOM mice (n = 4) and anti–IL-22 treated mice (n = 4). Gated on live, Epcam+, CD45− cells. (D) Cyclin D1 expression in dysplastic epithelial cells of Hh+AOM mice after 1 wk isotype or anti–IL-22 treatment (top). Cyclin D1 mRNA expression in isolated EC (bottom). (E) mRNA expression in EC. Data are shown as means and SEM of n = 2–5 per group. Results are representative of at least two independent experiments. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001, one-way ANOVA with Bonferroni’s post test (E) or unpaired Student’s t test (C and D).
Figure 7. IL-22 regulates epithelial functions through Stat3 phosphorylation. (A–E) Hh+AOM-treated mice were injected with isotype control, anti–IL-22, anti-IL6R, anti–IL-17, or anti-Thy1 (B and E) for 1 wk. (A) Colonic phospho-Stat3-Y705 expression (bars, 25 µm). Arrows indicate pStat3+ cells in the cLP. (B) Immunoblot for phospho-Stat3 and total Stat3 in colonic epithelial and lamina propria cells. (C and D) Blocking of IL-22 reduces epithelial proliferation. (C) Ki-67 expression in freshly isolated EC from Hh+AOM mice (n = 4) and anti–IL-22 treated mice (n = 4). Gated on live, Epcam+, CD45− cells. (D) Cyclin D1 expression in dysplastic epithelial cells of Hh+AOM mice after 1 wk isotype or anti–IL-22 treatment (top). Cyclin D1 mRNA expression in isolated EC (bottom). (E) mRNA expression in EC. Data are shown as means and SEM of n = 2–5 per group. Results are representative of at least two independent experiments. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001, one-way ANOVA with Bonferroni’s post test (E) or unpaired Student’s t test (C and D).CC BY-NC-SA · PubMed Central
Figure 8. Presence of IL-22+ T cells and IL-22+ lineage-negative cells in human CRC. (A) huCRCs show an aberrant pattern of Ki-67 expression (left). IL-22+ cells are located in proximity to dysplastic areas (right). (B) Representative immunofluorescence image of a tumor and adjacent normal tissue (n = 4). CD3 (green), IL-22 (red), and DAPI (blue) are shown. Yellow arrows indicate CD3+ IL-22+ double-positive cells. White arrows indicate CD3− IL-22+ cells. (C and D) Flow cytometry of cLPs isolated from a huCRC and treated overnight with IL-23 followed by 3 h in the presence of PMA, ionomycin, and monensin (n = 3). (C) Lineage+ and lineage− CD45+ cells express intracellular IL-22. (n = 3). (D) Presence of IL-22 and IL-17 double-producing cells in human tumors (n = 3). (E) Cytokine expression in huCRC. mRNA expression of IL22, IL17, IL10, and IFNg in the colonic mucosa of matched tumors and adjacent normal tissue (n = 12) relative to bACT. Graph shows the percentage of matched tumor (T)-normal (N) tissue specimens, expressing the same levels of cytokines or more than twofold increased levels in either tumor or normal tissue.
Figure 8. Presence of IL-22+ T cells and IL-22+ lineage-negative cells in human CRC. (A) huCRCs show an aberrant pattern of Ki-67 expression (left). IL-22+ cells are located in proximity to dysplastic areas (right). (B) Representative immunofluorescence image of a tumor and adjacent normal tissue (n = 4). CD3 (green), IL-22 (red), and DAPI (blue) are shown. Yellow arrows indicate CD3+ IL-22+ double-positive cells. White arrows indicate CD3− IL-22+ cells. (C and D) Flow cytometry of cLPs isolated from a huCRC and treated overnight with IL-23 followed by 3 h in the presence of PMA, ionomycin, and monensin (n = 3). (C) Lineage+ and lineage− CD45+ cells express intracellular IL-22. (n = 3). (D) Presence of IL-22 and IL-17 double-producing cells in human tumors (n = 3). (E) Cytokine expression in huCRC. mRNA expression of IL22, IL17, IL10, and IFNg in the colonic mucosa of matched tumors and adjacent normal tissue (n = 12) relative to bACT. Graph shows the percentage of matched tumor (T)-normal (N) tissue specimens, expressing the same levels of cytokines or more than twofold increased levels in either tumor or normal tissue.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 529

Metadata

Authors
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F.
Affiliations
  • John Radcliffe Hospital (GB)
  • University of Oxford (GB)
Corresponding author
Powrie, Fiona
Venue
Journal of Experimental Medicine
Published
2013-04-15
Volume
210
Issue
5
Pages
917-931
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2124499950
Cited by
529
References
52
Citations by year
2026: 18 · 2025: 12 · 2024: 24 · 2023: 33 · 2022: 39 · 2021: 34 · 2020: 54 · 2019: 51 · 2018: 42 · 2017: 55 · 2016: 48 · 2015: 54 · 2014: 50 · 2013: 12
FWCI
30.21
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
Funders
  • Royal College of Pathologists of Australasia
  • Wellcome Trust (095688/Z/11/Z, 095688)
  • Cancer Research UK (A7297, A11663)
  • National Institute for Health and Care Research
  • European Commission (223151)
  • Jean Shanks Foundation
  • Austrian Science Fund
  • Genentech
  • Biotechnology and Biological Sciences Research Council (BB/I005609/1)
  • NIHR Oxford Biomedical Research Centre
  • UCB Celltech
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
colon cancer, IL-22, IL-17, innate lymphoid cells, inflammatory bowel disease, STAT3 phosphorylation, epithelial cell proliferation, therapeutic target
MeSH terms
Interleukin-22, Animals, Antigens, Ly, Cell Transformation, Neoplastic, Colitis, Colon, Colonic Neoplasms, Disease Models, Animal, Epithelial Cells, Humans, Interleukins, Lymphocytes, Phosphorylation, CD4 Antigens, Gene Expression Regulation, Neoplastic, Helicobacter, Disease Progression, Cell Lineage, STAT3 Transcription Factor, Mice, Natural Cytotoxicity Triggering Receptor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.